Financial Data and Key Metrics Changes - Revenue reached $241 million, representing reported revenue growth of 2% and organic revenue declines of 2% [7] - Adjusted gross margins held at 46% and adjusted EBITDA margin was 22%, both in line with expectations [8][29] - Non-GAAP adjusted earnings per share was $0.76, up 4% versus the prior year [29] - Operating cash flow for the quarter was $15 million compared to $41 million in the prior year, primarily driven by timing of tax payments and increased inventory purchases [29][30] Business Line Data and Key Metrics Changes - New product revenue grew by over 50% year over year, with a vitality index climbing to 21% of total sales [33] - Advanced surgery business experienced 17% growth year over year, driven by strong patient procedural growth rates [35] - Robotics and automation business unit revenue was up nearly 16% year over year, with a book to bill ratio of 1.05 [34] - Precision medicine business saw a 13% decline in sales year over year, but grew 10% sequentially [35] Market Data and Key Metrics Changes - Sales to medical device markets remained strong, driving sustained double-digit growth in advanced surgery [11] - Sales to industrial capital equipment saw declines year over year, but revenue has stabilized and bookings are rising at a double-digit pace [18] - Total China sales were up 15% year over year, despite challenges related to tariffs [80] Company Strategy and Development Direction - Long-term growth strategy focuses on markets with secular tailwinds such as precision and AI-driven robotics, minimally invasive surgery, and precision medicine [10] - The company aims to expand its portfolio into high-growth areas, increasing recurring consumables revenue to approximately 15% of sales [11] - The acquisition of Keon Technologies is expected to enhance the company's capabilities in RFID and AI-enhanced cloud-based software [30][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $50 million of incremental new product revenue for 2025, mainly due to strong outlook for next-generation medical devices [12] - The company is optimistic about the growth in physical AI applications, expecting sales to double in 2026 versus 2025 [15] - Management acknowledged the impact of tariffs but indicated that mitigation strategies are in place, with a focus on regional manufacturing [37][40] Other Important Information - The company expects full-year 2025 GAAP revenue to be approximately $970 million to $985 million, representing overall revenue growth of 2% to 4% [41] - Adjusted EBITDA for the full year of 2025 is expected to be $225 million to $230 million, or approximately a 23% EBITDA margin [42] - The company has a strong balance sheet and credit facility, positioning it well for future acquisitions [47] Q&A Session Summary Question: Can you break down your revenue guidance? - The full year guidance indicates reported organic growth will likely be down 1% to up 1% [53] Question: What is the FX implied impact for benefit? - The FX impact is expected to carry forward from the second quarter [55] Question: What are the biggest drivers of organic growth in 2026? - Key drivers include advanced surgery product ramps, physical AI applications, and strong design wins [60][64] Question: Have we seen the low point for the year in industrial and precision medicine? - Management believes the industrial business has reached its bottom and will improve sequentially [72] Question: What is the status of the $35 million held up due to tariffs? - This amount is factored into guidance, and recovery is not assumed yet [79] Question: Can you elaborate on the warehouse robotics win? - The technology involves sensing and fast, safe reactions, essential for advanced warehouse automation [90]

Financial Data and Key Metrics Changes - Revenue for the second quarter reached $241 million, representing a reported revenue growth of 2% and organic revenue declines of 2% [6][24] - Adjusted gross margins held at 46%, while adjusted EBITDA margin was 22%, both in line with expectations [7][28] - Non-GAAP adjusted earnings per share was $0.76, up 4% year over year [28] - Operating cash flow decreased to $15 million compared to $41 million in the prior year, primarily due to timing of tax payments and increased inventory purchases [28][29] Business Line Data and Key Metrics Changes - Medical market sales represented 54% of total sales, while advanced industrial markets accounted for 46% [30] - Advanced surgery business experienced 17% growth year over year, driven by strong patient procedural growth rates [33] - Revenue from the robotics and automation business unit was up nearly 16% year over year [32] - Precision medicine business saw a 13% decline in sales year over year, but grew 10% sequentially [33][34] Market Data and Key Metrics Changes - Customer orders grew 10% year over year and 20% sequentially, indicating a strengthening outlook [7] - Sales to medical device markets remained strong, with sustained double-digit growth in advanced surgery [10] - Total China sales increased by 15% year over year, despite uncertainties related to tariffs [75] Company Strategy and Development Direction - Long-term growth strategy focuses on markets with secular tailwinds, such as precision and AI-driven robotics, minimally invasive surgery, and precision medicine [8][10] - The company aims to expand its portfolio into high-growth areas, increasing recurring consumables revenue to approximately 15% of sales [10] - The acquisition of Keon Technologies is expected to enhance the company's capabilities in RFID and AI-enhanced software solutions [29][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $50 million of incremental new product revenue for 2025, mainly due to strong outlook for next-generation medical devices [11][24] - The company anticipates that the advanced surgery business revenue will nearly double by 2026 [11] - Despite challenges in the industrial capital equipment market, bookings are rising at a double-digit pace, indicating stabilization [18] Other Important Information - The company is committed to delivering sequential revenue and profit growth driven by innovation and operational discipline [37] - Tariff impacts are being mitigated through strategic shifts in production and cost reduction plans [35][36] - The company expects full-year 2025 GAAP revenue to be approximately $970 million to $985 million, representing overall revenue growth of 2% to 4% [38] Q&A Session Summary Question: Can you break down your revenue guidance? - The full-year organic growth is expected to be down 1% to up 1%, with the key driver being the Keon acquisition [52][56] Question: What are the biggest drivers of organic growth in 2026? - Key drivers include the continuation of advanced surgery product ramps, growth in physical AI applications, and strong design wins [57][61] Question: Have we seen the low point for the year in industrial and precision medicine? - Management believes both businesses have reached their bottom and expect sequential improvement moving forward [68][69] Question: What is the status of the $35 million held up due to tariffs? - This amount is factored into guidance, and recovery is not yet assumed due to ongoing uncertainties [74][75] Question: Can you elaborate on the warehouse robotics win? - The technology involves sensing capabilities and servo drives, essential for advanced warehouse automation applications [82][84]